about
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.Human papillomavirus and survival of patients with oropharyngeal cancer.Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..Enlargement and transformation of thyroglossal duct cysts in response to radiotherapy: imaging findingsDevelopment of a software for quantitative evaluation radiotherapy target and organ-at-risk segmentation comparison.Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organs-at-risk margination using daily CT on- rails imagingRadiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.The effect of independent collimator misalignment on the dosimetry of abutted half-beam blocked fields for the treatment of head and neck cancer.Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapyBeam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous CarcinomaIntensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort.Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck ModulePrediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinomaDisease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma.Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer.Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy.Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck.Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancerParotidectomy in the treatment of aggressive cutaneous malignancies.Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.Institutional clinical trial accrual volume and survival of patients with head and neck cancer.Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy.The symptom burden of treatment-naive patients with head and neck cancer.Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcomeQuality assurance assessment of diagnostic and radiation therapy-simulation CT image registration for head and neck radiation therapy: anatomic region of interest-based comparison of rigid and deformable algorithms.Lymphedema outcomes in patients with head and neck cancerLong-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade surveyTarget coverage for head and neck cancers treated with IMRT: review of clinical experiences.Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma.Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?Comparison of measurement methods with a mixed effects procedure accounting for replicated evaluations (COM3PARE): method comparison algorithm implementation for head and neck IGRT positional verificationSimple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancerCharacteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
P50
Q27313572-CEA1A237-C4A0-49CC-B11D-C27DF865722BQ27851567-78D0355C-127B-43DD-BC01-60764C49643CQ27853302-D9A70678-0397-4E83-8512-9C015B90A669Q28306209-AA77441C-4812-4CF7-A998-30DFFB40B075Q30486369-6A0D25F2-2505-423B-B769-999AE641E58AQ30809590-ABBB9701-8781-4E0A-93C0-122D7E59FF55Q31151565-4DBA2CCA-3C9E-4D0C-BF7B-6C0C53F8E214Q31221879-4927E9D4-A91F-410E-AA06-E964FBD104E2Q33615813-F966F958-64F2-470C-9F57-4A19EA54B3B3Q33667338-32BB30CD-F45C-436A-B3E8-8D77967D727CQ33779881-B40EB8B1-FD29-4420-8E23-356AD232CDDEQ33809120-E5D7AF78-AEA2-4746-97C1-CD1457F2B990Q33809126-10126923-ECEF-4848-A66F-AC436EA27E3FQ33809135-E13F12B7-B795-4925-BF0C-2987B3108F53Q33893165-09565AA2-FAB4-46CD-8A8D-33AD841A5D68Q34015012-6942B504-20C7-4983-8A4C-3DCE217487D2Q34015079-30840867-0E63-42DD-8909-969D9EE15372Q34171999-4A12252F-6C4F-4E9B-A782-4F85CF64D416Q34232203-C66D4DEC-2C71-4A44-9AE4-7B0BFFF1CEE8Q34287961-6003F2A1-CC43-4C1E-B911-DF9500A484E6Q34299614-2B452996-6C6A-425F-B420-855FBC12FC41Q34332841-6AFF42D4-535A-40F5-9C6E-CA0C1A4B478BQ34344547-B40463A3-E692-4825-AA87-9BBF40A51A4EQ34561555-7555E6F8-0A68-4700-8DE9-D34AEAA99588Q34615769-8EF7DE01-8A0F-47FA-9FC8-E933F3744467Q34633148-8C221549-8E9F-4807-ACC6-7AE7D7D3AE2CQ34768949-F57007DC-8CFC-49D2-820F-75509DC719FFQ34786079-5B0BB3D0-29B4-4C04-97B2-D394550F3B3DQ35010369-5A21FD8E-1A30-4176-8AB4-DFDD973C3CC9Q35117546-CC0B2283-B429-4557-AF7A-6AF79AEF5921Q35160630-8596E262-C125-4597-A0D8-0DAAD774F6B0Q35174711-A4039A0B-67F4-432C-9264-CFC9898EB9E1Q35428333-495E3C17-7354-49E5-9F57-225883797541Q35582536-CA06E809-A7DE-4631-92C9-0D3918899010Q35750405-050AE995-CB6F-49D8-BBB0-7863BA994996Q35750428-C6B23A0A-DC71-41B7-BCDD-C130E4331D0EQ35752309-03388825-1025-4084-8698-65FF4F62CD9EQ35756671-394A2F81-A926-4217-89BC-69BD1A665AADQ35839993-B9A5FC62-70FE-4E04-BC0F-36190B05815FQ35853734-4EA54CEA-25FC-441E-9216-518C20B2EA48
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David I Rosenthal
@ast
David I Rosenthal
@en
David I Rosenthal
@es
David I Rosenthal
@nl
type
label
David I Rosenthal
@ast
David I Rosenthal
@en
David I Rosenthal
@es
David I Rosenthal
@nl
prefLabel
David I Rosenthal
@ast
David I Rosenthal
@en
David I Rosenthal
@es
David I Rosenthal
@nl
P106
P1153
7403187442
P21
P31
P496
0000-0001-7124-7447